Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization study
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Growth differentiation factor 15 (GDF15) is a key regulator of body weight in animals by regulating food intake. Its receptor, glial cell-derived neurotrophic factor receptor alpha-like (GFRAL), was identified recently. Pre-clinical studies showed that it is a promising therapeutic target for cardiometabolic diseases and anorexia/cachexia. Although many pharmaceutical companies are developing drugs targeting GFRAL, whether the findings from animal studies can be extrapolated to man is unknown. Mendelian randomization (MR) is useful in investigating the relationship between risk factors and disease outcomes. We aimed to use a two-sample MR approach to evaluate the clinical usefulness of targeting GDF15 for cardiometabolic diseases. METHODS: Genetic instruments and summary statistics for MR analyses were obtained from a large genome-wide association study (GWAS) of GDF15 and cardiometabolic outcomes (n = 27,394 to 644,875), including body mass index, waist-hip ratio, waist circumference, whole-body lean mass, fat percentage, Type 2 Diabetes, fasting glucose, glycated haemoglobin, fasting insulin, LDL-cholesterol, HDL-cholesterol, total cholesterol, triglycerides, coronary artery disease, and estimated BMD (eBMD). Conventional inverse variance weighted (IVW) method was adopted to obtain the causal estimates of GDF-15 with different outcomes; weighted median and MR-egger were used for sensitivity analyses. FINDINGS: There was null association between GDF15 levels and anthropometric outcomes. One SD increase in genetically-determined GDF15 was significantly associated with reduced HDL-C (beta: -0.048SD; SE: 0.014; P = .001) but the result was not significant in sensitivity analyses. A consistent significant causal association was observed between GDF15 and eBMD in IVW (beta: 0.026 SD; SE: 0.005; P < .001) and subsequent sensitivity analyses. INTERPRETATION: This study sheds lights on the potential of drugs targeting the GDF15/GFRAL axis. It suggested that the effect of targeting GDF15/GFRAL axis for weight control in human may be different from the effects observed in animal studies. GDF15 treatment may improve BMD in humans. FUND: No specific funding was received for this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816 · cited 8×
“No significant pleiotropic effectwas observed in theMR-Egger intercept.”
MethodInfluentialBowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922
Verbanck, M., Chen, C.-Y., Neale, B., & Do, R. (2018) · Nature Genetics · doi:10.1038/s41588-018-0099-7 · Cited by 8,591
Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data
Burgess, S., Butterworth, A., & Thompson, S. G. (2013) · Genetic Epidemiology · doi:10.1002/gepi.21758 · Cited by 6,050
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Calculating statistical power in Mendelian randomization studies.
Brion, M.-J. A., Shakhbazov, K., & Visscher, P. M. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt179 · Cited by 1,751
New genetic loci link adipose and insulin biology to body fat distribution
The ADIPOGen Consortium, Shungin, D., The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The GEFOS Consortium, The GENIE Consortium, The, G. L. G. C., The, I. C. B. P., The International Endogene Consortium, Study, T. L. C., et al. (2015) · Nature · doi:10.1038/nature14132 · Cited by 1,580 · cited 4×
“The currentMR study utilized summary statistics of the genetic instruments of GDF-15 from the GWAS or genome-wide meta-analysis of BMI [11], WHR [12], WC [12], WBLM [13], fat percentage [14], T2D [15], FG [16], FI [16], A1c [17], HDL-C [18], LDL-C [18], TC [18], TG [18], CAD [19] and eBMD [20].”
MethodInfluentialLoss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Evacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801 · cited 8×
“Indeed,Mendelian randomization (MR) analysis in 2012 showed that serumHDLC levels are not associated with CVD events, suggesting that conductingMR study before RCTmaybe necessary and important clinically.”
ResultInfluential
Cited by
GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease
Wang, D., Day, E. A., Townsend, L. K., Djordjevic, D., Jørgensen, S. B., & Steinberg, G. R. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00529-7 · Cited by 516
GDF15: a hormone conveying somatic distress to the brain
Lockhart, S. M., Saudek, V., & O’Rahilly, S. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa007 · Cited by 256
Synergistic insights into human health from aptamer- and antibody-based proteomic profiling
Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Kerrison, N. D., Oerton, E., Koprulu, M., Luan, J., Hingorani, A. D., Williams, S. A., Wareham, N. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27164-0 · Cited by 234
Overview of growth differentiation factor 15 in metabolic syndrome
Asrih, M., Wei, S., Nguyen, T. T., Yi, H., Ryu, D., & Gariani, K. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17725 · Cited by 70
The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update
Arkoumani, M., Papadopoulou-Marketou, N., Nicolaides, N. C., Kanaka-Gantenbein, C., Tentolouris, N., & Papassotiriou, I. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1678565 · Cited by 64
“COPD patients had higher levels of GDF-15 in lung tissues, causing a higher incidence of respiratory inflammation, mucus over secretion, and muscle dysfunction with subsequent respiratory atrophy and reduced quality of life [3].”
BackgroundInfluential
Metadata
- Authors
- Cheung, C.-L., Tan, K. C. B., Au, P. C. M., Li, G. H. Y., & Cheung, B. M. Y.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 41
- Pages
- 85-90
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2914625922
- Cited by
- 48
- References
- 20
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization study. https://app.cochat.ai/papers/10.1016/j.ebiom.2019.02.021
- The paper
- Cheung, C.-L., Tan, K. C. B., Au, P. C. M., Li, G. H. Y., & Cheung, B. M. Y. (2019). Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization study. EBioMedicine. https://doi.org/10.1016/j.ebiom.2019.02.021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.